Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

News

Meth, Crack, Coke and Ecstasy: Effects on HIV Disease Progression

April 24, 2015

Meth, Crack, Coke and Ecstasy: Effects on HIV Disease Progression

Stimulant use (e.g., methamphetamines) may have less of a negative effect on health outcomes for people living with HIV than previously thought. A team of researchers, in an article published in JAIDS, reported that they found no association between any frequency of stimulant use and mortality, and only a modest association between high-frequency stimulant use and the combined outcomes of mortality and progression to AIDS.

Over 1,000 HIV-positive men who have sex with men participating in the Multicenter AIDS Cohort Study (MACS) provided information for the study about methamphetamine, cocaine, crack cocaine, or ecstasy use. In addition, MACS researchers collected participant data of AIDS-defining illnesses, CD4 cell counts, viral loads, and mortality. On average, participants stayed in the study for about eight and a half years, during which time they completed study visits every three months.

The researchers analyzed participant data to look at the relationship between frequency of stimulant use and the likelihood of progressing to AIDS or dying, while controlling for outside influences such as hepatitis C co-infection, high blood pressure, high cholesterol, depression, drinking, and smoking.

Advertisement
"We thought there would be this dose response relationship where people who had used more often, or reported use more frequently, would have more negative health outcomes. They would die faster, or they would progress to AIDS or die faster," explains Adam Carrico, PhD, of Department of Community Health Systems, School of Nursing, University of California, San Francisco, and lead author of the paper.

Unexpectedly, they didn’t find a significant association between stimulant use over time and mortality.

"We found that when people are on HAART [highly active antiretroviral therapy], there are not mortality differences between stimulant users and non-users. Being a drug user didn’t mean that you died faster," says Carrico.

This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.

More From This Resource Center


Undetectable Viral Load and HIV Prevention: What Do Gay and Bi Men Need to Know?

Do HIV-Negative Gay Men Need Condoms if They're on PrEP? Here's What I Tell My Patients


Related Stories

Ask Our Expert, David Fawcett, Ph.D., L.C.S.W., About Substance Use and HIV
More on Gay Men, Substance Abuse and HIV/AIDS


This article was provided by BETA. Visit their website at www.betablog.org.
 

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.